Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Antovic

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 2, 2002
Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIIIJ P Antovic, A Antovic, S He, et al.
Thrombosis Research|May 5, 2007
Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndromeMika Skeppholm, N Håkan Wallén, Karin Malmqvist, et al.
Thrombosis and Haemostasis|October 4, 2002
Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?J P Antovic, R Rafik Hamad, A Antovic, et al.
International Journal of Laboratory Hematology|June 25, 2013
The evaluation of two automated soluble fibrin assays for use in the routine hospital laboratoryE Westerlund, B J Woodhams, J Eintrei, et al.
Scientific Reports|March 16, 2021
The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generationMojca Božič Mijovski, Rickard E Malmström, Nina Vene, et al.
International Journal of Laboratory Hematology|April 11, 2012
Comparison of five point-of-care D-dimer assays with the standard laboratory methodJ P Antovic, K Höög Hammarström, G Forslund, et al.
Thrombosis and Haemostasis|November 22, 2013
Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demandAleksandra Antovic, Danijela Mikovic, Ivo Elezovic, et al.
The British Journal of Oral & Maxillofacial Surgery|June 9, 2020
Is there thrombin-activatable fibrinolysis inhibitor in saliva?S Chopra, E Friman, C W Krüger, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|February 22, 2005
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?J P Antovic, S Schulman, S S A An, et al.
Journal of Electrocardiology|January 6, 2020
Substantial prevalence of subclinical cardiovascular diseases in patients with hemophilia A evaluated by advanced electrocardiographyYanan Zong, Maren Maanja, Roza Chaireti, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 2, 2002
Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIIIJ P Antovic, A Antovic, S He, et al.
Thrombosis Research|May 5, 2007
Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndromeMika Skeppholm, N Håkan Wallén, Karin Malmqvist, et al.
Thrombosis and Haemostasis|October 4, 2002
Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?J P Antovic, R Rafik Hamad, A Antovic, et al.
International Journal of Laboratory Hematology|June 25, 2013
The evaluation of two automated soluble fibrin assays for use in the routine hospital laboratoryE Westerlund, B J Woodhams, J Eintrei, et al.
Scientific Reports|March 16, 2021
The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generationMojca Božič Mijovski, Rickard E Malmström, Nina Vene, et al.
International Journal of Laboratory Hematology|April 11, 2012
Comparison of five point-of-care D-dimer assays with the standard laboratory methodJ P Antovic, K Höög Hammarström, G Forslund, et al.
Thrombosis and Haemostasis|November 22, 2013
Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demandAleksandra Antovic, Danijela Mikovic, Ivo Elezovic, et al.
The British Journal of Oral & Maxillofacial Surgery|June 9, 2020
Is there thrombin-activatable fibrinolysis inhibitor in saliva?S Chopra, E Friman, C W Krüger, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|February 22, 2005
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?J P Antovic, S Schulman, S S A An, et al.
Journal of Electrocardiology|January 6, 2020
Substantial prevalence of subclinical cardiovascular diseases in patients with hemophilia A evaluated by advanced electrocardiographyYanan Zong, Maren Maanja, Roza Chaireti, et al.
Pageof 5